Table 2.

Population estimates and medians and 95% confidence intervals from the bootstrap evaluations (weeks 16 and 52)

Parameter	Week 16		Week 52
	Estimate	Bootstrap median (95% confidence interval)	Estimate	Bootstrap median (95% confidence interval)
PASI75
Placebo response	0.078	0.077 (0.049, 0.109)	—	—
Emax	0.939	0.938 (0.915, 0.967)	1a	—
EC50 (μg/mL)	0.203	0.197 (0.081, 0.407)	0.300	0.298 (0.214, 0.401)
Exponent for effect of baseline hs‐CRP on EC50	0.649	0.660 (0.323, 1.00)	—	—
PASI90
Placebo response	0.031	0.030 (0.013, 0.053)	—	—
Emax	0.812	0.812 (0.769, 0.872)	1a	—
EC50 (μg/mL)	0.441	0.434 (0.170, 0.990)	0.956	0.958 (0.761, 1.20)
Exponent for effect of baseline hs‐CRP on EC50	0.616	0.618 (0.293, 0.952)	—	—
PASI100
Placebo response	0.011	0.010 (0.001, 0.024)	—	—
Emax	0.642	0.641 (0.541, 0.856)	0.933	0.931 (0.718, 0.998)
EC50 (μg/mL)	—	—	2.88	2.88 (1.04, 3.89)
EC50 for Asian race (μg/mL)	9.65	9.80 (4.93, 18.8)	—	—
EC50 for Non‐Asian races (whites or other) (μg/mL)	2.36	2.31 (0.974, 5.66)	—	—
Exponent for effect of baseline hs‐CRP on EC50	0.296	0.299 (0.109, 0.548)	—	—
sPGA0/1
Placebo response	0.069	0.068 (0.042, 0.099)	—	—
Emax	0.916	0.916 (0.882, 0.967)	1a	—
EC50 (μg/mL)	0.431	0.424 (0.194, 0.891)	0.709	0.710 (0.565, 0.883)
Exponent for effect of baseline hs‐CRP on EC50	0.505	0.508 (0.211, 0.806)	—	—

The effect of baseline hs‐CRP on EC₅₀ was incorporated using power model by normalizing baseline hs‐CRP with median value in data set (2.94 mg/L). e.g., ${\text{EC}}_{50}={\text{EC}}_{50-\mathrm{estimate}}\ast {\left(\frac{\text{hs}-\text{CRP}}{2.94}\right)}^{\mathrm{exponent}}$.

EC₅₀, concentration producing 50% of maximum effect; E_max, maximum effect; hs‐CRP, high‐sensitivity C‐reactive protein; PASI, Psoriasis Area and Severity Index; sPGA, static Physician's Global Assessment.

^aThe estimate was close to 1, fixing it to 1 allowed for estimation of its precision.